The potential of gene therapy to treat premalignant disease or recurrent cancer has not been investigated. The goal of the present investigation was to explore the efficacy of prodrug-mediated, suicide gene therapy as a strategy to treat incipient neoplasia in stratified squamous epithelium. To test this strategy, a tissue model of premalignancy was generated by mixing normal human keratinocytes (NHK) that express the bacterial cytosine deaminase gene (CD) with premalignant keratinocytes which have been genetically marked with the bacterial gene for ␤-galactosidase (II-4-␤-gal) in skin-like organotypic cultures. Preliminary studies in monolayer cultures demonstrated that CD-transduced NHK (NHK/CD) efficiently expressed the transgene and deaminated the pro-drug 5-fluorocytosine (5FC) to the toxic product 5-fluorouracil (5FU). The capacity of NHK/CD to kill II-4-␤-gal cells through bystander effect was assayed in both submerged culture and in the organotypic model of premalig-
Introduction
Up to half of all primary oral cancers will recur after surgical excision. 1 This is due to genetic and phenotypic alterations near the primary tumor, which are not clinically apparent, but predispose this epithelium to recurrent cancer. Such 'field cancerization' is defined as carcinogen-induced, genetic alterations throughout the oral mucosa which result in elevated risk for malignant progression at multiple sites in that individual. 2 Local therapies have been unable to prevent multiple and often extensive recurrent lesions or treat field carcinogenesis in a significant way, leaving patients susceptible to the development of further disease. Treating such recurrent cancers with additional surgical procedures is not always an option because of functional and/or cosmetic impairment.
An optimal strategy to prevent recurrent oral cancer would be to treat the premalignant lesion as it develops de novo from previously normal tissue. Incipient neoplasia in stratified epithelium is initiated as a small nest nancy. In submerged cultures, it was found that CDmediated killing of II-4-␤-gal cells did not require cell-cell contact and that the LD 50 of 5FC for efficient bystander killing of II-4-␤-gal was 0.5 mM. When this concentration of prodrug was used in organotypic cultures, a significant number of dysplastic II-4-␤-gal cells were eliminated from the tissue. Bystander killing of II-4-␤-gal cells was related to the number of NHK/CD present. These findings demonstrated that potentially malignant keratinocytes could be eliminated from a dysplastic tissue through activation of pro-drug and killing of adjacent cells through the bystander effect. By establishing an in vitro model to eliminate premalignant cells using suicide gene therapy, these studies provide a new approach for the treatment of incipient cancer as it develops, thereby preventing invasive disease. Gene Therapy (2001) 8, 232-238.
of dysplastic cells expands in the context of more normal cells to form a macroscopic tumor. 3, 4 An approach to successfully limit neoplastic progression in a premalignant lesion would depend on the capacity to kill dysplastic foci at an early stage of neoplastic development. However, there are no investigations that have specifically studied the capacity of a therapeutic agent to target and eliminate potentially malignant cells in a premalignant tissue due to the lack of tissue models that would allow the efficacy of such treatment to be directly monitored. We recently developed a novel organotypic tissue model, which simulates premalignancy in stratified epithelium and in which nests of marked, dysplastic keratinocytes could be identified and monitored in the context of normal cells. 5 This organotypic culture system provides a novel preclinical model to study the efficacy of treating premalignant disease.
One approach, which has not been tested, yet may be well-suited to the treatment of premalignant disease, is suicide gene therapy. This gene therapy strategy involves the transfer and expression of non-mammalian genes encoding enzymes that convert nontoxic pro-drug into toxic antimetabolites, which render the tumor and neighboring cells (via the bystander effect) sensitive to their cytotoxic action. [6] [7] [8] Antineoplastic potential of suicide gene therapy has been demonstrated in treating advanced cancers [9] [10] [11] using the suicide gene cytosine deaminase (CD). CD encodes a bacterial enzyme that can convert non-toxic 5-fluorocytosine (5FC) to the toxic anabolite 5-fluorouracil (5FU) 12, 13 resulting in efficient killing of genetically modified mammalian cells as well as nontransduced cells in the microenvironment. 6 Regression of tumors expressing the CD gene was achieved in animal studies in the presence of 5FC without generating significant systemic toxicity. [14] [15] [16] However, exploitation of this strategy for elimination of premalignant disease in stratified epithelium has not been attempted.
The goal of this investigation was to study the efficacy of suicide gene therapy in this tissue model of premalignant disease. NHK were transduced with retrovirus carrying the CD2 gene (NHK/CD) 17 and were mixed with genetically marked cells with malignant potential to generate dysplastic, premalignant tissues. Experiments in monolayer cultures demonstrated NHK/CD-mediated killing of non-transduced, potentially malignant cells which was mediated by a bystander effect which did not require cell contact. In premalignant, organotypic cultures the presence of pro-drug and adjacent NHK/CD significantly decreased the tumor volume of II-4-␤-gal cells. This study establishes proof of concept that targeting a fraction of cells in a premalignant tissue can eliminate significant numbers of potentially malignant cells. Such a strategy provides a new approach to the control of premalignant disease in stratified epithelium.
Results
CD2-transduced keratinocytes (NHK/CD) deaminate cytosine and are sensitive to 5-fluorocytosine To verify that NHK/CD expressed the CD gene, flow cytometric analysis was performed with an anti-CD antibody 18 and demonstrated that about 90% of keratinocytes grown in mass cultures expressed the transgene while no expression was seen in mock-infected keratinocyte cultures (data not shown). To determine that CD expressed by keratinocytes was enzymatically active, the conversion of cytosine to uracil was assayed using cell extracts prepared from NHK/CD. In order to define the optimal conditions for infection that would allow maximal expression of CD in NHK/CD, cells were transduced at two multiplicities of infection (MOI = 1 or 10 p.f.u./ml) and grown with or without G418. NHK/CD grown with G418 for 6 days (Figure 1d To assess the sensitivity of NHK/CD to 5FC, CDmediated killing was assayed by determining the colonyforming efficiency (CFE) of NHK/CD grown in the presence of increasing concentrations of 5FC (Figure 2 ). The dose-response curve generated demonstrated a direct correlation between pro-drug concentration and growth inhibition of NHK/CD cells. Low concentrations of 5FC (0.1 mm) caused a 40% decrease in CFE compared to cells grown without 5FC, while highest concentrations of 5FC (10 mm) caused the growth inhibition of all CD-modified keratinocyte colonies. Since only 90% of cells transduced in mass culture expressed the CD transgene, this suggested that some NHK clones were killed through a 
CD-mediated bystander killing eliminates premalignant keratinocytes in organotypic cultures
We then hoped to determine if pro-drug treatment of premalignant organotypic cultures containing a fraction of NHK/CD cells could cause bystander-mediated killing of premalignant II-4-␤-gal cells in a tissue with three-dimensional tissue architecture. These two cell types were mixed at 1:1 and 2:1 ratios (NHK/CD: II-4-␤-gal), and were treated with 5FC after 4 days so that cultures could begin to stratify. Cultures were exposed to 5FC for an additional 8 or 12 days and then formalin-fixed and stained with hematoxylin and eosin to assess morphology as well as immunostained for ␤-gal expression to determine the distribution and fate of II-4-␤-gal. In the absence of 5FC, pure cultures of NHK/CD (Figure 4a ) generated a stratified epithelium which underwent complete morphologic differentiation while pure II-4-␤-gal cultures (Figure 4c ) generated a well-stratified epithelium demonstrating severe dysplasia, altered tissue architecture and the absence of morphologic differentiation after 8 day exposure. When these cultures were treated with 5FC (0.5 mm) for 8 days, no alteration in the growth of pure II-4-␤-gal cells was seen (Figure 4d ) while NHK/CD cultures were dramatically thinner and did not undergo stratification or morphologic differentiation (Figure 4b ). Since pro-drug was added on day 4, when cultures were partially stratified, it appears that addition of 5FC had caused the growth arrest of these cells. When NHK/CD and II-4-␤-gal cells were mixed at 1:1 (Figure 4e and g) and 2:1 (Figure 4i and k) ratios and grown without 5FC, dysplastic tissues were generated with foci of differentiated cells (arrows, Figure 4i ) surrounded by adjacent dysplastic cells. Immunohistochemical staining demonstrated that these foci were NHK/CD that did not express ␤-gal while surrounding cells were II-4-␤-gal cells (Figure 5c and e). When these mixtures were treated with 5FU, all cultures were atrophic and demonstrated disrupted tissue architecture (Figure 4f , h, j, l). Mixtures exposed to 5FC for 12 days (Figure 4h and l) were thinner and underwent greater tissue destruction than those exposed to the pro-drug for 8 days (Figure 4f and j) . In addition, cytopathic effects including cytoplasmic swelling and nuclear degeneration were seen in cultures treated for 12 days (Figure 4h and l) . Immunhistochemical staining for ␤-gal revealed that few NHK/CD without (a, c, e, g, i, k) or with (b, d, f, h, j, l remained in the 1:1 mixtures after 12 days exposure to 5FC (Figure 5d ) while no NHK/CD remained in the 2:1 mixtures (Figure 5f ). In addition, the numbers of II-4-␤-gal cells remaining in cultures which were originally mixed at a 2:1 ratio were less than those remaining in 
Figure 5 Elimination of premalignant II-4-␤-gal cells through bystander killing is increased by the presence of a greater number of NHK/CD cells. Immunohistochemistry was performed to distinguish between ␤-galexpressing, II-4-␤-gal cells and non-expressing NHK/CD in cultures grown at the air-liquid interface for 12 days. Pure cultures of II-4-␤-gal cells demonstrated expression in all constituent cells of cultures either exposed (b) or not exposed (a) to 5FC. Cultures mixed at a 1:1 ratio and exposed to 5FC demonstrated small numbers of ␤-gal-negative NHK/CD cells (d, arrow) and larger numbers of these cells in non-treated controls (c, arrow). When II-4-␤-gal and NHK/CD were mixed at a 2:1 ratio, larger numbers of ␤-gal-negative NHK/CD were seen in cultures not treated with 5FC (e, arrow). NHK/CD cells and most II-4-␤-gal cells were eliminated when 2:1 mixtures were grown in the presence of 5FC (f). The dermal-epidermal interface is marked

Discussion
There are no current clinical gene therapy trials designed for premalignant disease at any tissue site in general and in the oral cavity in particular. This is surprising since premalignant oral lesions are particularly well-suited for treatment with gene therapy, which presents several advantages over current gene therapy approaches and conventional treatments of oral cancer. First, the superficial nature of such precancerous lesions allows access for gene delivery and clinical evaluation of treatment response. Second, since the volume of intraepithelial tumor cells is relatively small, gene therapy for precancer would require eliminating smaller numbers of tumor cells to lead to a cure than would treatment of advanced disease. Third, due to the bystander effect, not all premalignant cells would need to express the suicide gene for therapy to be effective. In this way, it may be possible to block neoplastic progression at an early stage and prevent oral cancer recurrence by targeting and eliminating relatively small numbers of premalignant cells. In this study, we have established parameters for effective elimination of intraepithelial tumor cells in a premalignant tissue. We have done so by using suicide gene therapy, which delivers a gene to these potentially malignant tumor cells and results in their sensitization to a prodrug, which kills cells when converted to its active metabolite. 19, 20 The efficacy of this approach has been studied for advanced oral squamous cell carcinoma but not for premalignant disease. In animal models of oral cancer, treatment of invasive tumors by direct injection of an adenoviral vector encoding herpes simplex virus (HSV)-thymidine kinase (TK) into the tumor mass effectively killed tumor cells using this suicide gene therapy approach. 21 In a different study, a large proportion of carcinoma cells were killed when as few as 10-20% of cells were transduced in vitro. 22 However, suicide gene therapy did not completely eliminate these advanced tumors nor did it provide significant increases in survival. 23 It appears that a suicide gene therapy approach for treatment of advanced malignancy is non-curative when there is a large tumor load, even with bystander effectmediated killing of adjacent, nonıtransformed cells. For this reason, the goal of the current study was to determine if suicide gene therapy strategies developed for the treatment of advanced neoplastic disease could be effective in the treatment of premalignant lesions.
We have shown that a significant number of intraepithelial cells with malignant potential could be eliminated from a stratified epithelium in which about 90% of normal cells expressed the recombinant CD gene. In addition, the number of premalignant cells that were eliminated was augmented by increasing the fraction of normal cells expressing the CD gene. This suggests that bystander-mediated killing of premalignant cells may be an attainable goal by transferring the CD gene to normal cells, obviating the need to target gene delivery only to dysplastic foci. While this may result in killing of normal cells as well, it is unlikely that tissue viability will be altered since the fraction of stem cells required for tissue survival is known to be relatively small. 24 An optimal treatment for premalignant disease would be one through which a toxic product could be spread locally within the tissue without requiring direct contact between dysplastic and suicide gene-expressing cells. This would allow elimination of larger clusters of dysplastic cells which might not be in contact with cells expressing the suicide gene product. Cell killing mediated by CD expression is well-suited for this purpose since the mechanism of CD-mediated bystander killing has previously been shown to occur through intercellular diffusion which is not dependent on cell-cell contact. 16 We demonstrated this mechanism of action in monolayer culture, where co-culture of II-4-␤-gal and NHK/CD resulted in II-4-␤-gal killing in pre-confluent cultures where these cell types were not contacting each other. Similarly, expression of CD in organotypic mixtures was able to eliminate large II-4-␤-gal clusters which contained cells not directly contacting NHK/CD. Due to this efficient diffusion-mediated killing, CD suicide gene therapy is likely to be more effective than HSV-TK suicide gene therapy, which depends on gap junctional intercellular communication and cell contact for efficient bystander killing. 25, 26 Since the diffusion of the toxic metabolite 5FU is likely to be limited, it will be important to transfer the CD-transgene to as many cells as possible throughout the premalignant tissue. This could be accomplished by direct intralesional injection of retroviral vectors, which has been previously been shown to result in sustained gene expression in a large number of transduced cells in vivo. 27 In addition, since transformed cells may not have a high degree of gap junctional intercellular communication, 28 HSV-TK may be of limited use in the treatment of these incipient lesions. CD-mediated bystander effect has previously been shown to be more effective than that of HSV-TK in both cell culture 29 and implanted tumors. 30 We demonstrated that complete elimination of all II-4-␤-gal cells did not occur in organotypic culture (Figure 5d,f) . This could be due to the death of NHK/CD cells after 5FC treatment, leading to a significant reduction of 5FU levels, thereby limiting II-4-␤-gal killing. It is likely that a larger number of normal cells would need to express a suicide gene for such treatment to result in complete eradication of a premalignant lesion. An alternative explanation for the presence of residual II-4-␤-gal cells after 5FC treatment is the generation of clones which are resistant to 5FU. In order to achieve complete elimination of premalignant cells, it may be necessary to combine suicide gene therapy with other existing cancer treatments. For example, the use of a bifunctional CD/HSV-TK fusion suicide gene, coupled with radiotherapy 31, 32 has been shown to be a highly efficient means of destroying tumor cells and such a combined therapy may be useful in treating premalignant lesions, as well.
Our studies have been facilitated by the development of a tissue model which mimics pre-cancer in stratified squamous epithelium. This was accomplished by generating tissues with correct three-dimensional tissue organization so that foci of dysplastic cells could be seen in the context of more normal cells. Using this model, we have previously shown that the fate and phenotype of premalignant cells could be monitored during early neoplastic progression 5, 33, 34 and have now demonstrated its use for preclinical studies on the efficacy of suicide gene therapy in premalignant disease. The current study has begun to characterize parameters for successful treatment of premalignant lesions with suicide gene therapy. We have found that by expressing the CD gene in a fraction of normal keratinocytes, large numbers of dysplastic foci can be eliminated from the tissue. We have shown that suicide gene therapy strategies developed for advanced oral malignancy may be useful in limiting malignant progression when applied at an early, premalignant stage. By eliminating relatively small numbers of premalignant cells at a stage at which disease progression can more easily be controlled, we hope to destroy their capacity for neoplastic progression and prevent disease progression in the oral cavity and at other sites.
Materials and methods
Cell culture
Normal human keratinocytes (NHK) were cultured from newborn foreskin by the method of Rheinwald and Green 35 in keratinocyte medium described by Wu et al. 36 Cultures were established through trypsinization of foreskin fragments and grown on irradiated 3T3 fibroblasts. 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% bovine calf serum. The keratinocyte cell line HaCaT-ras (clone II-4) was grown in DMEM containing 5% fetal calf serum. This cell line was generated by transfecting the spontaneously immor-talized human keratinocyte line HaCaT 37 with an activated c-Harvey-ras oncogene. 38 These II-4 cells demonstrated severe dysplasia in organotypic cultures, lowgrade malignant behavior after grafting to nude mice 5 and probably represent cells at an early stage of neoplastic progression. Organotypic cultures were prepared by adapting the protocol developed by Organogenesis Inc. 39 Briefly, early passage human dermal fibroblasts were added to neutralized type I collagen (Organogenesis, Canton, MA, USA) to a final concentration of 2.5 × 10 4 cells/ml. Three ml of this mixture were added to each 35-mm polycarbonate insert of a six-well plate and incubated for 4 to 6 days, until the collagen matrix showed no further shrinkage. At this time, a total of 5 × 10 5 keratinocytes, II-4-␤-gal cells or mixtures of these two cell types were plated on the contracted collagen gel. Cultures were maintained submerged in low calcium epidermal growth media (EGM) (Organogenesis) for 2 days, submerged for 2 days in normal calcium EGM and grown at the air-liquid interface by feeding from below with normal calcium EGM for 3 days. Cultures were treated with 0.5 mm 5FC when raised to an air-liquid interface. Medium containing 5FC was replaced every two days.
Enzymatic assay for cytosine deaminase An in vitro assay for cytosine deaminase activity was performed as described by Mullen et al 17 with minor modifications. Cells (1 × 10 6 ) were washed twice with 1 × PBS and resuspended in 120 l of 100 mm Tris, pH 7.8; 1 mm EDTA; 1 mm DTT. The cells were subjected to three cycles of freeze-thawing and the material was then centrifuged. Supernatant was transferred to a new tube and total protein concentration was determined using BioRad protein assay (Bio-Rad, Hercules, CA, USA). Fifteen g of total cellular proteins were combined with 1 l of ( 3 H) cytosine (1 mCi/ml, specific activity 14.7 Ci/mmol) and incubated for 15 min at 37°C. Five l from this reaction volume or 4 l of a control marker solution containing unlabeled cytosine (0.4 mg/ml) and unlabeled uracil (0.4 mg/ml) in water were placed on thin-layer chromatography sheets (Whatman) and developed in a mixture of 1-butanol (86%)/water (14%). After drying, bands corresponding to cytosine and uracil were cut out under short-wave UV and assayed in a scintillation spectrometer.
Retroviral vector titration and transduction of keratinocytes
The CD2 vector is a Moloney murine leukemia virusbased vector which contains the bacterial gene for cytosine deaminase under the control of the viral 5′ long-terminal repeat region and neomycin phosphotransferase gene (neo r ) under the control of the SV40 early promoter. 17 CD2 was pseudotyped with the G protein of vesicular stomatitis virus (VSV-G) envelope protein by transiently transfecting 293GP/CD2 cells with pHCMV-G. 40 Viral supernatants were collected 36-72 h later, filtered and concentrated 10-fold by centrifugation at 12 000 r.p.m. for 60 min. Aliquots of viruses were stored at −80°C. 293GP/CD2 cells were prepared by transducing 293GP cells with supernatant from confluent amphotropic producer pCD2-PA317 cells. 17 Clones with a high level of CD expression were isolated by limiting dilution. Titers of pseudotyped CD2 virus were determined to be 3.2 × 10 7 colony-forming unit/ml after transducing NIHGene Therapy 3T3 cells with serial viral dilutions. Transduction was performed as described 41 using MOI = 1 p.f.u./ml or MOI = 10 p.f.u./ml in the presence of polybrene (8 g/ml).
Cytotoxicity assay NHK/CD cells were plated at clonal density and allowed to adhere overnight. Various concentrations of 5FC (Sigma, St Louis, MO, USA) were then added to the medium and cells were selected for 12 days in G418 (0.8 mg/ml). Colony-forming efficiency was determined by comparing the number of colonies grown in the presence of 5FC compared with the number of colonies grown in the absence of 5FC after staining with 1% rhodamine.
Immunofluorescence Specimens were frozen in embedding media (Triangle Biomedical, Durham, NC, USA) in liquid nitrogen vapors after being placed in 2 m sucrose for 2 h at 4°C. Tissues were serial sectioned at 6 m and mounted on to gelatinchrome alum-coated slides (Sigma). Tissue sections were washed with PBS and blocked with 10 mg/ml goat IgG, 0.05% goat serum, and 0.2% BSA, vol/vol in PBS without fixation. Sections were incubated with rabbit polyclonal antiserum to bacterial-galactosidase (Cortex Pharmaceuticals, San Leandro, CA, USA) and detected with FITCconjugated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA). Slides were coverslipped with Vectashield containing 1 g/ml DAPI (Vector Laboratories). Fluorescence was visualized using a Nikon OptiPhot microscope (Melville, NY, USA) and double exposure photomicroscopy was performed using a FITC filter to detect ␤-gal-expressing cells. For routine light microscopy, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin and 4 m sections were stained with hematoxylin and eosin.
Flow cytometry
Numbers of ␤-gal-expressing cells in mixtures of II-4-␤-gal and NHK/CD were determined by using the DetectaGene Green CMFDG lacZ Gene Expression kit (Molecular Probes, Eugene, OR, USA). After trypsinization and centrifugation, cells were resuspended at a density of 10 6 cells/ml in 100 ml of DMEM medium supplemented with 10% FBS and containing 50 mm of the fluorogenic substrate 5-chloromethylfluorescein di-␤-dgalactopyranoside (CMFDG). Verapamil (0.1 mm), which blocks the efflux of fluorescent products produced by the reaction, was added and the reaction mixtures were incubated at 37°C for 30 min and stored on ice. In order to eliminate dead cells from the assay, propidium iodide (1.5 mm) was added to the samples shortly before the analyses. Samples were analyzed by FACScan cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA).
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